Krka DD (FRA:KN8) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KN8 Krka DD FRA:KN8
71 GF Score
Price €263.00
GF Value €185.83
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Krka DD FFO per Share?

FFO per Share only applies to REITs.

FRA:KN8
71GF Score
Krka DD FRA:KN8
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Krka DD (FRA:KN8) Overvalued in 2026?

Based on GuruFocus' analysis, Krka DD stock appears to be overvalued. The current stock price of €263.00 is trading 41.5% above its estimated GF Value™ of €185.83. GuruFocus considers Krka DD to be Significantly Overvalued.

Key valuation signals for FRA:KN8:

  • FFO per Share:
  • GF Value™: €185.83 vs. price of €263.00 (41.5% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krka DD Business Description

Address Smarjeska Cesta 6, Novo Mesto, SVN, 8501
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
71GF Score

Get the complete analysis for FRA:KN8

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€263.00
Price
€185.83
GF Value